Stoke Therapeutics, Inc. Common Stock (STOK) is a publicly traded Healthcare sector company. As of July 5, 2026, STOK trades at $32.70 with a market cap of $2.04B and a P/E ratio of -11.51. STOK moved -0.03% today. Year to date, STOK is +2.77%; over the trailing twelve months it is +183.12%. Its 52-week range spans $5.35 to $40.22. Analyst consensus is strong buy with an average price target of $47.83. Rallies surfaces STOK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Stoke Therapeutics Posts -4.63 ROIC/WACC, Best Among Biopharma Peers: Stoke Therapeutics has a ROIC of -45.41% against a 9.80% WACC, yielding a ROIC/WACC ratio of -4.63. This ratio is the highest (least negative) among clinical-stage biopharma peers, surpassing Revolution Medicines’ -6.44, Gossamer Bio’s -35.84 and Atreca’s -15.46.
| Metric | Value |
|---|---|
| Price | $32.70 |
| Market Cap | $2.04B |
| P/E Ratio | -11.51 |
| EPS | $-2.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.22 |
| 52-Week Low | $5.35 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $32.08M |
| Net Income | $-169.77M |
| Gross Margin | 0.00% |
8 analysts cover STOK: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $47.83.